Mark G. Lebwohl
Mark G. Lebwohl is an American dermatologist and author who is Professor and Chairman Emeritus of the Kimberly and Eric J. Waldman Department of Dermatology and the Dean for Clinical Therapeutics at the Icahn School of Medicine at Mount Sinai in New York City.Lebwohl's books include the book on dermatologic therapy, ''Treatment of Skin Disease'' (), as well as ''Atlas of the Skin and Systemic Disease'' (). He has authored more than 500 publications, multiple book chapters and has been named as one of New York Magazine’s “Best Doctors” every year since the inception of the annual list. Dr. Brian S. Kim is director of a Center for Neuroinflammation and Sensation named in Mark Lebwohl's honor at Icahn School of Medicine at Mount Sinai. Provided by Wikipedia
Showing 1 - 20 results of 22 for search 'Mark Lebwohl', query time: 0.10s
Refine Results
-
1
-
2
-
3
-
4
-
5
-
6
-
7
-
8
Real-World Long-Term Effectiveness of Risankizumab Among Patients with Moderate-to-Severe Psoriasis: Analysis from an International Medical Chart Review (RAPID) Study by Andreas Pinter, Ahmed M. Soliman, Irina Pivneva, Roksana Ghanbariamin, Min Yang, Bang Truong, Luis Puig, Mark Lebwohl
Published 2024Connect to this object online.
Book -
9
Impact of psoriasis disease severity and special area involvement on patient-reported outcomes in the real world: an analysis from the CorEvitas psoriasis registry by Bruce Strober, Kristina Callis Duffin, Mark Lebwohl, Adam Sima, Jud Janak, Manish Patel, Huzefa Photowala, Vishvas Garg, Jerry Bagel
Published 2024Connect to this object online.
Book -
10
-
11
Integrated Safety Analysis on Skin Cancers among Patients with Psoriasis Receiving Ixekizumab in Clinical Trials by Saxon D. Smith, Alexandros Stratigos, Matthias Augustin, Jose Manuel Carrascosa, Susanne Grond, Elisabeth Riedl, Wen Xu, Himanshu Patel, Mark Lebwohl
Published 2023Connect to this object online.
Book -
12
Six-Month Real-World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis Registry by Mark Lebwohl, Bruce Strober, Amy Schrader, Alvin H. Li, Thomas Eckmann, Baojin Zhu, William N. Malatestinic, Julie Birt, Meghan Feely, Andrew Blauvelt
Published 2024Connect to this object online.
Book -
13
Complete Skin Clearance is Associated with the Greatest Benefits to Health-Related Quality of Life and Perceived Symptoms for Patients with Psoriasis by Matthias Augustin, Alice B. Gottlieb, Mark Lebwohl, Andreas Pinter, Richard B. Warren, Luis Puig, Rhys Warham, Jérémy Lambert, Susanne Wiegratz, Balint Szilagyi, Andrew Blauvelt
Published 2024Connect to this object online.
Book -
14
Notalgia Paresthetica Dermatologist Report of Symptom Burden and Treatment: Results from a Physician Survey by Brian S. Kim, Sonja Ständer, Kenji Kabashima, Jennifer A. Mohawk, Sherri So, Joana Goncalves, Nilam Shah, Catherine Munera, Joseph C. Punzalan, Romelia Argudo, Mark Lebwohl
Published 2024Connect to this object online.
Book -
15
-
16
The Efficacy and Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus Panel by Joshua Burshtein, Milaan Shah, Danny Zakria, Benjamin Lockshin, Jeff Crowley, Joseph F. Merola, Ken Gordon, Mona Shahriari, Neil J. Korman, Raj Chovatiya, Robert Kalb, Mark Lebwohl
Published 2024Connect to this object online.
Book -
17
Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results) by Jerry Bagel, John Nia, Peter W. Hashim, Manmath Patekar, Ana de Vera, Sophie Hugot, Kuan Sheng, Summer Xia, Isabelle Gilloteau, Elisa Muscianisi, Andrew Blauvelt, Mark Lebwohl
Published 2018Connect to this object online.
Book -
18
Safety of Secukinumab from 1 Million Patient-Years of Exposure: Experience from Post-Marketing Setting and Clinical Trials by Rui Sun, Mercedes Bustamante, Venkatesh Kumar Gurusamy, Mark Lebwohl, Alice B. Gottlieb, Philip J. Mease, Atul Deodhar, Weibin Bao, Meryl Mendelson, Brian Porter, Deepa Chand, Victor Dong
Published 2024Connect to this object online.
Book -
19
Publisher Correction: Long-Term Health-Related Quality of Life in Patients with Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Randomised Phase 3 Stu... by Paolo Gisondi, Alice B. Gottlieb, Boni Elewski, Matthias Augustin, Sandy McBride, Tsen-Fang Tsai, Christine de la Loge, Frederik Fierens, José M. López Pinto, Nicola Tilt, Mark Lebwohl
Published 2023Connect to this object online.
Book -
20
Long-Term Health-Related Quality of Life in Patients with Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Randomised Phase 3 Studies (CIMPASI-1 and CI... by Paolo Gisondi, Alice B. Gottlieb, Boni Elewski, Matthias Augustin, Sandy McBride, Tsen-Fang Tsai, Christine de la Loge, Frederik Fierens, José M. López Pinto, Nicola Tilt, Mark Lebwohl
Published 2022Connect to this object online.
Book